PARP inhibitors: Treating mCRPC from a genetic basis
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC
Nivolumab/ipilimumab continues to show improved survival, durable response in aRCC
Mixed results reported for nivolumab/ipilimumab in cisplatin-ineligible mUC
EV plus pembrolizumab doubles CR rate vs chemotherapy in la/mUC